SCYNEXIS, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1999-01-01

Employees: 51

Market Cap: $56M

Website: http://www.scynexis.com

Clinical Trials

Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis

Phase 2

Terminated

Conditions: Invasive Pulmonary Aspergillosis

Interventions: Drug: SCY-078
Drug: Voriconazole
Other: Oral Placebo Tablets

First Posted Date: 2018-09-14

Last Posted Date: 2024-08-09

Lead Sponsor: Scynexis, Inc.

Target Recruit Count: 22

Registration Number: NCT03672292

Locations: 🇩🇪
Universitaetsklinikum Koeln, Klinisches Studienzentrum 2 für Infektiologie, Klinik I für Innere Medizin Kerpener Str. 62, Bettenhaus Ebene 15 Raum 64, Köln, Germany
🇧🇪
Hematology Department AZ Sint-Jan Brugge - Oostende AV Campus Brugge Ruddershove 10 8000, Brugge, Belgium
🇨🇦
University Health Network at the University of Toronto, Toronto, Ontario, Canada

and more 5 locations

Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)

Phase 3

Completed

Conditions: Candidiasis, Invasive
Candidemia

Interventions: Drug: SCY-078

First Posted Date: 2017-12-06

Last Posted Date: 2024-07-03

Lead Sponsor: Scynexis, Inc.

Target Recruit Count: 30

Registration Number: NCT03363841

Locations: 🇺🇸
Scynexis, Inc., Jersey City, New Jersey, United States
🇮🇳
Amrita Institute of Medical Sciences (AIMS), Kanayannur, Kochi, India
🇮🇳
St John's Medical College and Hospital, Bangalore, Karnataka, India

and more 9 locations

Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis

Phase 2

Completed

Conditions: Candida Vulvovaginitis

Interventions: Drug: Fluconazole
Drug: SCY-078

First Posted Date: 2017-08-17

Last Posted Date: 2021-08-12

Lead Sponsor: Scynexis, Inc.

Target Recruit Count: 186

Registration Number: NCT03253094

Locations: 🇺🇸
Drexel University, Philadelphia, Pennsylvania, United States
🇺🇸
Wake Research Associates, LLC, Raleigh, North Carolina, United States
🇺🇸
New Age Medical Research Corp., Miami, Florida, United States

and more 21 locations

Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

Phase 3

Completed

Conditions: Invasive Candidiasis
Allergic Bronchopulmonary Aspergillosis
Chronic Pulmonary Aspergillosis
Mucocutaneous Candidiasis
Coccidioidomycosis
Blastomycosis
Other Emerging Fungi
Histoplasmosis
Invasive Pulmonary Aspergillosis
Recurrent Vulvovaginal Candidiasis

Interventions: Drug: Ibrexafungerp

First Posted Date: 2017-02-23

Last Posted Date: 2024-11-20

Lead Sponsor: Scynexis, Inc.

Target Recruit Count: 233

Registration Number: NCT03059992

Locations: 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
University of Texas Health Science Center at Houston, Houston, Texas, United States
🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States

and more 34 locations

Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis

Phase 2

Completed

Conditions: Vulvovaginal Candidiasis

Interventions: Drug: SCY-078
Drug: Fluconazole

First Posted Date: 2016-02-10

Last Posted Date: 2019-07-12

Lead Sponsor: Scynexis, Inc.

Target Recruit Count: 96

Registration Number: NCT02679456

Locations: 🇩🇴
Hospital Dr. Francisco E. Moscoso Puello, Santo Domingo, Dominican Republic
🇩🇴
Instituto Dermatologico y Cirugia de Piel, Santo Domingo, Dominican Republic

Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis

Phase 2

Completed

Conditions: Mycoses
Candidiasis, Invasive
Candidemia

Interventions: Drug: SCY-078
Drug: Fluconazole
Drug: Micafungin

First Posted Date: 2014-09-19

Last Posted Date: 2024-06-25

Lead Sponsor: Scynexis, Inc.

Target Recruit Count: 27

Registration Number: NCT02244606

Locations: 🇺🇸
University of Texas Health Science Center at Houston, Houston, Texas, United States
🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
South Texas Veterans Healthcare System, San Antonio, Texas, United States

and more 27 locations

Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients

Phase 1

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: SCY-635
Drug: Placebo

First Posted Date: 2011-02-07

Last Posted Date: 2014-11-06

Lead Sponsor: Scynexis, Inc.

Target Recruit Count: 57

Registration Number: NCT01290965

Locations: 🇺🇸
Quest Clinical Research, San Francisco, California, United States
🇺🇸
McGuire Veterans Affairs Medical Center, Richmond, Virginia, United States

Study of SCY-635, Pegasys and Copegus in Hepatitis C

Phase 2

Completed

Conditions: Hepatitis C Infection

Interventions: Drug: Placebo
Drug: SCY-635
Drug: Pegasys
Drug: Copegus

First Posted Date: 2010-12-23

Last Posted Date: 2017-08-18

Lead Sponsor: Scynexis, Inc.

Target Recruit Count: 10

Registration Number: NCT01265511

Locations: 🇺🇸
Alamo Medical Research, San Antonio, Texas, United States
🇺🇸
Quest Clinical Research, San Francisco, California, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy